Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Goldfinch Bio is raising $69,708,309.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Anthony Johnson played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Goldfinch Bio

Goldfinch is singularly focused on discovering and developing precision therapies for patients with kidney disease. Chronic kidney disease (CKD) is a growing, global health epidemic that places an enormous social and economic burden on patients, their families, and society. Goldfinch brings together experts in the field and experienced leaders with a shared mission to pioneer new treatments for patients with kidney disease.

To learn more about Goldfinch Bio, visit http://www.goldfinchbio.com/

Contact:
Anthony Johnson, President and Chief Executive Officer
617-585-2000
https://www.linkedin.com/in/anthonygjohnson/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved